T-Cell Reinfusion After Interfering With Lymphocyte Binding Location of AIDS Virus Through Zinc-finger-nuclease Elimination of CCR5 Receptors: The TRAILBLAZER Study
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs SB 728 T (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAILBLAZER
- 22 Jul 2019 Status changed from not yet recruiting to recruiting.
- 17 May 2019 Planned initiation date changed from 30 Apr 2019 to 30 May 2019.
- 08 May 2019 Planned initiation date changed from 30 Mar 2019 to 30 Apr 2019.